tess-ah-MORE-eh-lin
An FDA-approved growth hormone releasing peptide that specifically reduces visceral (belly) fat.
Also known as: Egrifta
FDA approved for: HIV-associated lipodystrophy (excess visceral fat)
Last reviewed: April 2026
Tesamorelin is a GHRH analog — like sermorelin, but with a trans-3-hexenoic acid modification that makes it more potent. It's FDA-approved specifically for reducing visceral abdominal fat. It stimulates natural GH production and has been shown to reduce liver fat and improve body composition.
Daily injection into abdomen
Frequency
Daily
Pain Level
●○○ Minimal
Self-Administered
Yes — at home
Typical Range
2mg daily
Month 1
GH/IGF-1 levels begin rising.
Month 3
Measurable reduction in visceral fat.
Month 6+
Significant visceral fat reduction and metabolic improvement.
Overall: Mild
Injection site reactions
Redness, itching, or swelling at site.
Joint pain
Related to GH elevation.
Peripheral edema
Mild swelling in hands/feet.
• Active malignancy
• Pregnancy
• Disruption of hypothalamic-pituitary axis
• Glucocorticoids — may reduce effectiveness
• Insulin — monitor blood sugar
Pregnancy: Contraindicated in pregnancy.
The only FDA-approved GHRH analog (for lipodystrophy). More potent than sermorelin. Used off-label for body composition in general population.
Sermorelin
A peptide that tells your pituitary gland to make more growth hormone naturally — supports sleep, recovery, and body composition.
CJC-1295
A long-acting growth hormone releaser that provides sustained GH stimulation over days rather than minutes.
CJC-1295 / Ipamorelin
The most popular growth hormone peptide combination — hits two pathways simultaneously for amplified GH release.
We don't currently offer this peptide — but we have protocols for similar goals.
Coming Soon →This is a compounded medication prescribed off-label. It has not been FDA-approved for the uses described. All prescribing decisions are made by your independent licensed provider.